Teleflex Incorporated (NYSE:TFX) Director Benson Smith sold 9,331 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $260.52, for a total transaction of $2,430,912.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Benson Smith also recently made the following trade(s):
- On Monday, April 2nd, Benson Smith sold 9,331 shares of Teleflex stock. The stock was sold at an average price of $251.49, for a total transaction of $2,346,653.19.
Shares of NYSE TFX traded up $3.94 during mid-day trading on Tuesday, hitting $266.46. 219,396 shares of the stock were exchanged, compared to its average volume of 313,459. The firm has a market cap of $11,601.09, a price-to-earnings ratio of 31.25, a PEG ratio of 1.90 and a beta of 1.17. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 0.89. Teleflex Incorporated has a twelve month low of $191.40 and a twelve month high of $288.78.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.04. The company had revenue of $595.10 million during the quarter, compared to analyst estimates of $601.17 million. Teleflex had a net margin of 7.11% and a return on equity of 16.46%. The company’s revenue was up 15.8% on a year-over-year basis. During the same quarter last year, the business posted $2.13 earnings per share. analysts forecast that Teleflex Incorporated will post 9.66 earnings per share for the current year.
Several research analysts recently issued reports on the stock. Goldman Sachs assumed coverage on shares of Teleflex in a research report on Wednesday, April 4th. They issued a “neutral” rating and a $257.00 price target for the company. Leerink Swann reissued a “buy” rating and issued a $321.00 price target (up previously from $307.00) on shares of Teleflex in a research report on Tuesday, January 30th. Stephens reissued a “buy” rating and issued a $300.00 price target on shares of Teleflex in a research report on Thursday, January 18th. TheStreet lowered shares of Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. Finally, ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $279.10.
Several hedge funds and other institutional investors have recently bought and sold shares of TFX. Cubist Systematic Strategies LLC increased its holdings in shares of Teleflex by 1,300.9% during the third quarter. Cubist Systematic Strategies LLC now owns 4,469 shares of the medical technology company’s stock worth $1,081,000 after buying an additional 4,150 shares in the last quarter. California Public Employees Retirement System increased its holdings in shares of Teleflex by 5.3% during the third quarter. California Public Employees Retirement System now owns 102,182 shares of the medical technology company’s stock worth $24,725,000 after buying an additional 5,182 shares in the last quarter. IFM Investors Pty Ltd acquired a new stake in shares of Teleflex during the third quarter worth approximately $338,000. Public Employees Retirement System of Ohio increased its holdings in shares of Teleflex by 59.1% during the third quarter. Public Employees Retirement System of Ohio now owns 32,728 shares of the medical technology company’s stock worth $7,919,000 after buying an additional 12,155 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Teleflex by 7.6% during the third quarter. Parametric Portfolio Associates LLC now owns 133,455 shares of the medical technology company’s stock worth $32,292,000 after buying an additional 9,399 shares in the last quarter. 90.90% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/benson-smith-sells-9331-shares-of-teleflex-incorporated-tfx-stock.html.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.